10-Q: Chemed Q3 Earnings Decline Amid Rising Costs, Cyber Incident

Chemed Corporation reported a decline in net income and diluted EPS for Q3 and the first nine months of 2025, despite revenue growth, driven by increased operating expenses and a new cybersecurity incident at its VITAS segment.

Summary

• Consolidated service revenues and sales increased 3.1% to $624.9 million for the three months ended September 30, 2025, compared to $606.181 million in the prior year.
• Net income decreased 15.2% to $64.237 million for Q3 2025, down from $75.776 million in Q3 2024.
• Diluted Earnings Per Share (EPS) fell 10.8% to $4.46 in Q3 2025, compared to $5.00 in Q3 2024.
• Adjusted EBITDA decreased 11.4% to $109.045 million in Q3 2025, with Adjusted EBITDA as a percentage of revenue declining to 17.4% from 20.3%.
• For the nine months ended September 30, 2025, service revenues and sales increased 5.5% to $1.89 billion, but net income decreased 11.0% to $188.487 million.
• VITAS segment revenue grew 4.2% in Q3 2025, driven by a 2.5% increase in days-of-care and a 4.1% Medicare reimbursement rate increase, but was negatively impacted by acuity mix shift and Medicare cap adjustments.
• Roto-Rooter segment revenue increased 1.1% in Q3 2025, with growth in plumbing, excavation, and water restoration, offset by a decrease in drain cleaning and independent contractor operations.
• Consolidated gross margin declined to 31.5% in Q3 2025 from 34.6% in Q3 2024, primarily due to increased Medicare Cap liability and variable patient care expenses at VITAS, and higher variable expenses at Roto-Rooter.
• A cybersecurity incident was detected at VITAS on October 24, 2025, involving data theft of protected health information (PHI) and a ransom demand, though no material impact on operations or financial systems is currently expected.
• The company repurchased $180.776 million of capital stock (407,500 shares) in Q3 2025 at an average price of $443.62 per share, and the Board authorized an additional $300 million for share repurchases on August 1, 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant declines in net income, EPS, and EBITDA despite revenue growth, indicating margin compression and increased operating costs. The new cybersecurity incident introduces an additional layer of risk and uncertainty. While the positive outcome of the VITAS legal proceeding is a relief, it doesn't fully offset the operational and financial headwinds.

Positives

• Consolidated service revenues and sales increased by 3.1% in Q3 2025 and 5.5% for the first nine months of 2025.
• VITAS segment revenue grew 4.2% in Q3 2025, driven by a 2.5% increase in days-of-care and a 4.1% Medicare reimbursement rate increase.
• Roto-Rooter segment saw revenue growth in plumbing (5.2%), excavation (5.9%), and water restoration (6.6%) in Q3 2025.
• An Administrative Law Judge (ALJ) ruled largely in favor of VITAS regarding a $50.3 million Medicare overpayment appeal, resulting in a de minimis overpayment and a refund of previously deposited amounts.
• The company maintains strong liquidity with approximately $404.5 million of unused lines of credit available as of September 30, 2025.
• Management anticipates operating income and cash flows will be sufficient to operate the business and meet commitments for the foreseeable future.
• The company is in compliance with all debt covenants as of September 30, 2025, and anticipates remaining in compliance.
• Increased cash dividends per share to $0.60 in Q3 2025 from $0.50 in Q3 2024, and to $1.60 for the nine months ended September 30, 2025, from $1.30 in the prior year.
• The Board of Directors authorized an additional $300 million for stock repurchases on August 1, 2025, demonstrating confidence in capital allocation.

Negatives

• Net income decreased 15.2% in Q3 2025 and 11.0% for the first nine months of 2025.
• Diluted EPS decreased 10.8% in Q3 2025 and 7.2% for the first nine months of 2025.
• Adjusted EBITDA decreased 11.4% in Q3 2025 and 8.8% for the first nine months of 2025.
• Consolidated gross margin declined to 31.5% in Q3 2025 from 34.6% in Q3 2024, and to 31.6% for the first nine months of 2025 from 34.6% in the prior year.
• VITAS gross margin declined due to a $3.8 million increase in Medicare Cap liability in Q3 2025 and increased variable patient care expenses and wages.
• Roto-Rooter's gross margin declined due to an increase in variable expenses.
• Selling, general and administrative (SG&A) expenses increased 6.5% in Q3 2025 (before long-term incentive compensation and market value adjustments), partly due to a $2.7 million severance accrual and a $2.3 million increase in legal expense at VITAS.
• Interest income decreased to $2.555 million in Q3 2025 from $3.668 million in Q3 2024, and to $7.186 million for the first nine months of 2025 from $11.405 million in the prior year.
• Market value adjustments on assets held in deferred compensation trusts decreased significantly for the nine months ended September 30, 2025, to $6.791 million from $16.600 million in the prior year.
• Roto-Rooter's drain cleaning revenues decreased 1.1% in Q3 2025 and 2.8% for the first nine months of 2025, primarily due to a decrease in job count.

Risks

• Macroeconomic trends and uncertainties, such as inflation and tariffs, may negatively affect net sales and profitability in the future.
• The heavily-regulated hospice industry subjects VITAS to inquiries and investigations by government agencies, which can result in penalties, repayment obligations, funding withholding, or debarment.
• Ongoing legal and regulatory matters can adversely affect the company through defense costs, potential payments, withholding of governmental funding, diversion of management time, and related publicity.
• VITAS is subject to Medicare payment limitations, including the Inpatient Cap and Medicare annual per-beneficiary cap, which can require repayment to the Federal government if exceeded.
• Concentration of accounts receivable from Medicare (66%) and Medicaid (28%) for VITAS exposes the company to significant government program risks.
• Reliance on a single pharmacy services provider and a single medical supplies vendor for the majority of VITAS's purchases could lead to operational disruptions, logistical challenges, and increased costs if these vendors experience issues.
• A cybersecurity incident at VITAS on October 24, 2025, involved data theft of protected health information (PHI) and a ransom demand, which could lead to regulatory and legal notifications, reputational damage, and unforeseen financial impacts despite current containment efforts.
• Changes in accounting standards, such as ASU 2023-09 (Income Tax Disclosure), ASU 2024-03 (Disaggregation of Income Statement Expenses), and ASU 2025-06 (Intangibles – Goodwill and Other – Internal Use Software), require ongoing analysis and may impact future financial disclosures and reporting.

Future Outlook

Management does not expect a material negative effect on net sales or profitability for the remainder of fiscal year 2025 from macroeconomic trends like inflation and tariffs. However, they are evaluating these factors and their potential effects, as well as strategies to offset cost increases through pricing actions and cost savings for fiscal year 2026 planning. The company anticipates that operating income and cash flows will be sufficient to operate the business and meet commitments for the foreseeable future, and expects to remain in compliance with all debt covenants.

Management Comments

• "We continue to monitor macroeconomic trends and uncertainties such as inflation, the effects of recently implemented tariffs, and the potential imposition of modified or additional tariffs, which may have adverse effects on net sales and profitability."
• "Based on preliminary analysis of the potential effects of the announced tariffs and these other factors, we do not expect a material negative effect on our net sales or profitability for the remainder of fiscal year 2025."
• "However, we are continuing to evaluate these factors and their potential effects as well as our ability to potentially offset all or a portion of cost increases through pricing actions and cost savings efforts for fiscal year 2026 planning."
• "Economic pressures including the challenges of high inflation and the effects of increased tariffs may negatively affect our net sales and profitability in the future."
• "Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources."
• "We anticipate that our operating income and cash flows will be sufficient to operate our business and meet any commitments for the foreseeable future."
• "Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future."
• "We are in compliance with all financial and other debt covenants as of September 30, 2025 and anticipate remaining in compliance throughout the foreseeable future."

Industry Context

Chemed operates in two distinct service industries: hospice care (VITAS) and plumbing/drain cleaning/water restoration (Roto-Rooter). The hospice industry is heavily regulated, with reimbursement rates and caps set by government programs like Medicare and Medicaid, which significantly influence revenue and profitability. VITAS's performance is directly tied to days-of-care, reimbursement rates, and managing acuity mix shifts, as well as navigating regulatory audits. The Roto-Rooter segment operates in the home and commercial services market, which can be influenced by housing market trends, consumer spending, and local economic conditions. Both segments are susceptible to macroeconomic pressures such as inflation impacting labor and material costs, which Chemed is actively monitoring for 2026 planning. The cybersecurity incident highlights the increasing threat landscape across all industries, particularly for healthcare providers handling sensitive patient data.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• VITAS was subject to an Office of the Inspector General's (OIG) audit regarding elevated level-of-care hospice services, with an initial recommendation for repayment of approximately $140.0 million.
• VITAS received a demand letter from its Medicare Administrative Contractor (MAC) seeking repayment of $50.3 million, which was appealed and deposited under immediate recoupment.
• On February 3, 2025, an Administrative Law Judge (ALJ) ruled that VITAS's care met Medicare's hospice standards for all but one day of the appealed claims.
• On March 18, 2025, the MAC reduced the total overpayment amount to a de minimis figure and refunded VITAS all previously unreturned deposited amounts in excess of that figure.
• The $46.968 million deposit with OAS was refunded on April 1, 2025.

Stakeholder Impact

• Shareholders: Negative impact on earnings per share and net income, but potential positive impact from increased share repurchase authorization and dividends. Cybersecurity incident introduces uncertainty.
• Employees: Severance accrual for one VITAS executive indicates management changes. Stock-based compensation plans are in place.
• Customers (VITAS patients): Continued provision of hospice care, including charity care ($2.3 million in Q3 2025). Cybersecurity incident potentially exposed protected health information (PHI).
• Customers (Roto-Rooter): Continued plumbing, drain cleaning, excavation, and water restoration services.
• Suppliers: VITAS relies on single vendors for pharmacy services and medical supplies, posing a risk of disruption.
• Creditors: Company remains in compliance with all debt covenants, indicating stable creditworthiness.

Next Steps

• Continue to evaluate macroeconomic factors (inflation, tariffs) and their potential effects on net sales and profitability for fiscal year 2026 planning.
• Implement pricing actions and cost savings efforts to offset potential cost increases in fiscal year 2026.
• Finalize the impacts of ASU 2023-09 (Income Tax Disclosure) for incorporation into the Annual Report on Form 10-K.
• Continue analyzing the impact of ASU 2024-03 (Disaggregation of Income Statement Expenses) and ASU 2025-06 (Intangibles – Goodwill and Other – Internal Use Software) on footnote disclosures and consolidated financial statements.
• Continue the investigation into the cybersecurity incident at VITAS to determine the full scope, nature, and impact.
• Make all required regulatory and legal notifications related to the cybersecurity incident based on investigation findings.

Key Dates

Recommendation

While Chemed's revenue growth is positive, the significant decline in net income, diluted EPS, and Adjusted EBITDA, coupled with contracting gross margins, indicates operational challenges and increased costs. The cybersecurity incident at VITAS introduces a new, material risk with unknown long-term implications, despite current containment efforts. The favorable resolution of the Medicare overpayment appeal is a positive, but it's overshadowed by the broader financial performance deterioration. The aggressive share repurchase program and increased dividends are supportive for shareholders, but the underlying business profitability trends are concerning. Given the mixed signals and new risks, a 'hold' recommendation is appropriate, advising investors to monitor the company's ability to improve margins, manage costs, and mitigate the cybersecurity fallout before making further investment decisions.

Keywords

Chemed, VITAS, Roto-Rooter, Hospice Care, Plumbing Services, Drain Cleaning, Water Restoration, SEC Filing, 10-Q, Earnings Report, Financial Results, Healthcare Services, Home Services, Medicare, Medicaid, Share Repurchase, Cybersecurity, Data Breach, Legal Proceedings, Corporate Governance, Financial Performance